Entries by Ryan Bledsoe

Fziomed, Inc. Named One of the 2026 Best Places to Work in Southern California

/in /by

Fziomed is headquartered in San Luis Obispo, California, and has been named one of the Best Places to Work in Southern California for the past four consecutive years. SAN LUIS OBISPO, California, September 2, 2026 — Fziomed, Inc. (“Fziomed” or the “Company”), a global leader in adhesion prevention biomaterials and surgical innovation, today announced it was […]

Fziomed Announces Clinical Results from Level I Study Evaluating Oxiplex Absorbable Gel for Spine Surgery

/in /by

Clinical study demonstrates Oxiplex reduces leg pain and neurological symptoms following lumbar spine surgery. SAN LUIS OBISPO, California, March 10, 2026 — Fziomed, Inc. (“Fziomed” or the “Company”), a recognized global leader in postsurgical adhesion prevention with the best-in-class synthetic, absorbable gel technology platform, today announced results from a prospective, randomized, double-blinded, multi-center clinical study demonstrating […]

Fziomed Commemorates One Millionth Patient Treated With Its Dual-Polymer Adhesion Barrier Technology

/in /by

Fziomed’s dual-polymer adhesion barrier technology platform is becoming a new standard of care as an adjunctive therapy. SAN LUIS OBISPO, California, Feb. 18, 2026 — Fziomed, Inc. (“Fziomed” or the “Company”), a recognized global leader in postsurgical adhesion prevention with the best-in-class synthetic, absorbable gel technology platform, today announced that the Company has surpassed treating one […]

Fziomed Initiates Commercialization of Oxiplex Gel in the United States

/in /by

Best-in-class, synthetic, absorbable gel for use as an adjunct in lumbar spine surgery for the reduction of leg pain and neurological symptoms now available in the United States. SAN LUIS OBISPO, California, Nov. 5, 2025 — Fziomed, Inc. (“Fziomed” or the “Company”), a recognized global leader in postsurgical adhesion prevention with the best-in-class synthetic, absorbable […]

Fziomed Gains FDA De Novo Classification Grant and Marketing Authorization for Oxiplex® Gel in Spine Surgery

/in /by

Oxiplex is the only FDA authorized intraoperative gel indicated as an adjunct to lumbar spinal surgery to reduce postoperative leg pain and neurological symptoms. Oxiplex gel has the potential to become a new standard of care as an adjunctive therapy. SAN LUIS OBISPO, California, July 8, 2025 — Fziomed, Inc. (“Fziomed” or the “Company”), a […]

Fziomed, Inc.
231 Bonetti Drive
San Luis Obispo, CA 93401
USA
Phone: +1 (805) 546-0610
Fax: +1 (805) 546-0571
Email: [email protected]

The following trademarks are owned by Fziomed, Inc. and registered in the United States and certain foreign jurisdictions: FZIOMED®, OXIPLEX®, OXIPLEX/SP®, DYNAVISC®, INTERPOSE®, INTERCOAT®, OXIPLEX/AP®, and OXIPLEX/IU®.

© 2026 Fziomed, Inc.
All rights reserved.

Privacy Policy

Website design RainCastle Communications.

Last update: Feb. 25, 2025

  • Contact